All In Biotech

Drug Trial Radar · NCT02558231

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Placebo-controlled, Phase 3b Study

Last checked: Nov 19, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 247 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

247

Actual

Start

May 1, 2016

Primary completion

Aug 29, 2019

Study completion Apr 20, 2020

Sponsor

Lead sponsor
ActelionJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Sep 23, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this clinical trial is to compare the efficacy and safety of an initial triple oral treatment regimen (macitentan, tadalafil, selexipag) versus an initial dual oral treatment regimen (macitentan, tadalafil, placebo) in newly diagnosed, treatment-naïve patients with pulmonary arterial hypertension.

Conditions

  • Pulmonary Arterial Hypertension

Interventions

  • MacitentanDrug

    Used open-label in both arms, 10 mg tablet, 1 tablet u.i.d.

  • TadalafilDrug

    Used open-label in both arms, 20 mg tablet, 1-2 tablets u.i.d.

  • SelexipagDrug

    Used double-blind in the triple oral treatment arm, 200 microgram tablet, 1-8 tablets b.i.d.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 26 in Pulmonary Vascular Resistance (PVR)Time frame: Baseline, Week 26

Locations

58 sites in 15 countries. Site status is shown where the registry gives one.

  • Arizona Pulmonary Specialists, LTD

    Phoenix, Arizona

  • UCSD Health Sciences

    La Jolla, California

  • UCLA Medical Center

    Los Angeles, California

  • Mayo Clinic Jacksonville

    Jacksonville, Florida

  • Cleveland Clinic Florida

    Weston, Florida

  • Piedmont Pulmonary and Critical Care Research

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • University of Iowa Hospitals & Clinics

    Iowa City, Iowa

  • Kentuckiana Pulmonary Associates

    Louisville, Kentucky

  • LSU Health Sciences Center

    New Orleans, Louisiana

  • Johns Hopkins School of Medicine

    Baltimore, Maryland

  • Tufts Medical Center

    Boston, Massachusetts

  • Boston University Medical Center

    Boston, Massachusetts

  • Washington University School of Medicine

    Saint Louis, Michigan

  • University of New Mexico Hospital

    Albuquerque, New Mexico

  • The Christ Hospital

    Cincinnati, Ohio

  • Allegheny General Hospital of Research

    Pittsburgh, Pennsylvania

  • UPMC Presbyterian

    Pittsburgh, Pennsylvania

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Houston Methodist Hospital

    Houston, Texas

  • Royal Prince Albert Hospital

    Camperdown, New South Wales, Australia

  • St. Vincents Hospital Sydney

    Darlinghurst, New South Wales, Australia

  • LKH -Universität Klinkum Graz

    Graz, Austria

  • Krankenhaus der Elisabethinen Linz

    Linz, Austria

  • AKH Wien

    Vienna, Austria

  • Hôpital Erasme

    Brussels, Belgium

  • UZ Leuven - Campus Gasthuisberg

    Leuven, Belgium

  • University of Calgary

    Calgary, Canada

  • University of Ottawa Heart Institute

    Ottawa, Canada

  • Vancouver General Hospital

    Vancouver, British Columbia, Canada

  • London Health Sciences Centre - Victoria Hospital

    London, Ontario, Canada

  • University of Toronto

    Toronto, Ontario, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

  • Institut Universitaire de Cardiologie et de Pneumologie de Québec

    Québec, Quebec, Canada

  • Aarhus University Hospital Skejby

    Aarhus, Denmark

  • Rigshospitalet Copenhagen

    Copenhagen, Denmark

  • CHU de Bicêtre

    Le Kremlin-Bicêtre, France

  • Universitätsklinikum Köln

    Cologne, Germany

  • Unversitätsklinikum Carl Gustav Carus

    Dresden, Germany

  • Universitätsklinikum Giessen

    Giessen, Germany

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.